KMT2A and leukemia: To determine the requirement for MBNL1 in leukemia in vivo, we transduced two primary patient AML samples bearing MLL fusions (one MLL-AF9 and one MLL-AF10) with shMBNL1-64 or a non-targeting (NT) control.